bioAffinity Technologies, Inc. — Regulatory Filings 2022

Aug 9, 2022

CORRESP 1 filename1.htm

VIA EDGAR CORRESPONDENCE

August 9, 2022

United States Securities and Exchange Commission

Office of Trade & Services

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

Attention: Ms. Taylor Beech

Re:
Registration
Statement on Form S-1
File
No. 333-264463

WITHDRAWAL OF REQUEST FOR ACCELERATION OF EFFECTIVENESS

Dear Ms. Beech:

Reference is made to a letter filed by bioAffinity Technologies, Inc. (the “Company”) as correspondence via EDGAR on August 8, 2022, in which the Company requested that the effectiveness of the above-captioned Registration Statement on Form S-1, as amended, be accelerated to 4:30 p.m., Eastern Daylight Time, on Tuesday, August 9, 2022, in accordance with Rule 461 under the Securities Act of 1933, as amended.

The Company is no longer requesting that such Registration Statement be declared effective at this time and hereby formally withdraws its request for acceleration of that effective date.

If you have any questions regarding this withdrawal, please contact the Company’s outside counsel, Wilhelm E. Liebmann of Dykema Gossett PLLC at (210) 554-5414.

| Very
truly yours, | |
| --- | --- |
| BIOAFFINITY
TECHNOLOGIES, INC. | |
| By: | /s/
Maria Zannes |
| Name: | Maria
Zannes |
| Title: | Chief
Executive Officer |

Field: Page; Sequence: 1; Options: Last

Field: /Page